Cargando…
Real-time MR tracking of AAV gene therapy with βgal-responsive MR probe in a murine model of GM1-gangliosidosis
Transformative results of adeno-associated virus (AAV) gene therapy in patients with spinal muscular atrophy and Leber’s congenital amaurosis led to approval of the first two AAV products in the United States to treat these diseases. These extraordinary results led to a dramatic increase in the numb...
Autores principales: | Taghian, Toloo, Batista, Ana Rita, Kamper, Sarah, Caldwell, Michael, Lilley, Laura, Li, Hao, Rodriguez, Paola, Mesa, Katerina, Zheng, Shaokuan, King, Robert M., Gounis, Matthew J., Todeasa, Sophia, Maguire, Anne, Martin, Douglas R., Sena-Esteves, Miguel, Meade, Thomas J., Gray-Edwards, Heather L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517204/ https://www.ncbi.nlm.nih.gov/pubmed/34703836 http://dx.doi.org/10.1016/j.omtm.2021.08.003 |
Ejemplares similares
-
GM1 Gangliosidosis: Mechanisms and Management
por: Rha, Allisandra K, et al.
Publicado: (2021) -
AAV-Mediated Gene Delivery in Adult GM1-Gangliosidosis Mice Corrects Lysosomal Storage in CNS and Improves Survival
por: Baek, Rena C., et al.
Publicado: (2010) -
AAVrh10 vector corrects pathology in animal models of GM1 gangliosidosis and achieves widespread distribution in the CNS of nonhuman primates
por: Hocquemiller, Michaël, et al.
Publicado: (2022) -
Human GLB1 knockout cerebral organoids: A model system for testing AAV9-mediated GLB1 gene therapy for reducing GM1 ganglioside storage in GM1 gangliosidosis
por: Latour, Yvonne L., et al.
Publicado: (2019) -
Genetics and Therapies for GM2 Gangliosidosis
por: Cachón-González, María Begoña, et al.
Publicado: (2018)